[go: up one dir, main page]

NO20020185L - Formuleringer av IL-11 - Google Patents

Formuleringer av IL-11

Info

Publication number
NO20020185L
NO20020185L NO20020185A NO20020185A NO20020185L NO 20020185 L NO20020185 L NO 20020185L NO 20020185 A NO20020185 A NO 20020185A NO 20020185 A NO20020185 A NO 20020185A NO 20020185 L NO20020185 L NO 20020185L
Authority
NO
Norway
Prior art keywords
formulations
Prior art date
Application number
NO20020185A
Other languages
English (en)
Other versions
NO20020185D0 (no
Inventor
Nicholas W Warne
Rebecca L Ingram
Shannon Macmillan
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of NO20020185D0 publication Critical patent/NO20020185D0/no
Publication of NO20020185L publication Critical patent/NO20020185L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20020185A 1999-07-15 2002-01-14 Formuleringer av IL-11 NO20020185L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35439099A 1999-07-15 1999-07-15
PCT/US2000/019347 WO2001005355A2 (en) 1999-07-15 2000-07-14 Formulations for il-11

Publications (2)

Publication Number Publication Date
NO20020185D0 NO20020185D0 (no) 2002-01-14
NO20020185L true NO20020185L (no) 2002-03-13

Family

ID=23393125

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020185A NO20020185L (no) 1999-07-15 2002-01-14 Formuleringer av IL-11

Country Status (13)

Country Link
US (2) US7033992B2 (no)
EP (1) EP1368486A4 (no)
JP (1) JP2003522735A (no)
AU (1) AU6102600A (no)
BR (1) BR0012429A (no)
CA (1) CA2379354A1 (no)
HU (1) HUP0301349A3 (no)
IL (2) IL147599A0 (no)
MX (1) MXPA02000525A (no)
NO (1) NO20020185L (no)
NZ (1) NZ516664A (no)
PL (1) PL360914A1 (no)
WO (1) WO2001005355A2 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6540993B1 (en) * 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CA2379354A1 (en) * 1999-07-15 2001-01-25 Genetics Institute, Inc. Formulations for il-115
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20080069796A1 (en) * 2006-07-31 2008-03-20 Kim Jong-Mook Low Dose Treatment with an Interleukin-11 Analog
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5401446B2 (ja) * 2007-04-26 2014-01-29 バイエル ヘルスケア エルエルシー 凍結貯蔵を目的とした、組み換えタンパク質溶液の安定化
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
TWI420342B (zh) * 2010-02-01 2013-12-21 Kinpo Elect Inc 多點受控端之遙控系統、方法與應用於該系統之遙控裝置
CN102319206A (zh) * 2011-09-28 2012-01-18 厦门特宝生物工程股份有限公司 一种稳定的重组人白介素-11水溶液及其制备方法
ES2932861T3 (es) * 2018-01-26 2023-01-27 Hoffmann La Roche Composiciones de IL-22 Fc y procedimientos de uso

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US585962A (en) * 1897-07-06 Charles f
US5215895A (en) 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
US5292773A (en) 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
US5371193A (en) * 1990-05-21 1994-12-06 Genetics Institute, Inc. - Legal Affairs Mammalian cytokine, IL-11
DK0546124T4 (da) 1990-08-29 2003-05-19 Inst Genetics Llc Hæmatopoiese-stimulatorer med flere domæner
US5292646A (en) 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5582821A (en) * 1994-07-22 1996-12-10 Genetics Institute, Inc. Methods for treating bleeding disorders
ATE216590T1 (de) * 1995-02-06 2002-05-15 Genetics Inst Arzneimittelformulierungen für il-12
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5679339A (en) * 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US5885962A (en) * 1996-04-05 1999-03-23 Amgen Inc. Stem cell factor analog compositions and method
WO1998002541A1 (en) * 1996-07-12 1998-01-22 Genentech, Inc. Gamma-heregulin
CA2379354A1 (en) * 1999-07-15 2001-01-25 Genetics Institute, Inc. Formulations for il-115

Also Published As

Publication number Publication date
HUP0301349A2 (hu) 2003-08-28
IL147599A0 (en) 2002-08-14
IL147599A (en) 2009-09-22
US7033992B2 (en) 2006-04-25
WO2001005355A3 (en) 2003-10-02
EP1368486A2 (en) 2003-12-10
US20060159656A1 (en) 2006-07-20
NZ516664A (en) 2003-06-30
CA2379354A1 (en) 2001-01-25
JP2003522735A (ja) 2003-07-29
HUP0301349A3 (en) 2005-12-28
AU6102600A (en) 2001-02-05
EP1368486A4 (en) 2009-04-01
WO2001005355A2 (en) 2001-01-25
PL360914A1 (en) 2004-09-20
MXPA02000525A (es) 2005-07-01
BR0012429A (pt) 2002-09-17
US20040057927A1 (en) 2004-03-25
NO20020185D0 (no) 2002-01-14

Similar Documents

Publication Publication Date Title
NO20020185L (no) Formuleringer av IL-11
IS2325B (is) Örgerðar samsetningar epleróns
NO20026001D0 (no) 3'-promedikamenter av 2'-deoksy-<Beta>-L-nukleosider
AR026045A1 (es) Formulaciones de liberacion prolongada de derivados de eritromocina
DE60008422D1 (de) Pour-on formulierungen
NO20021834L (no) Orale formuleringer av anti-tumorforbindelser
ATE333866T1 (de) Lipasehemmer enthaltende dispersionsformulierungen
NO20015670D0 (no) Forbedrede farmasöytiske formuleringer
DE60019960D1 (de) Herstellung von isobutencopolymere
IS6398A (is) Lyfjablöndur
DE60038118D1 (de) Formulierungen von wachstumshormonen
ID30226A (id) Komposisi penat rambut
NO20021860D0 (no) Formulering av substituerte benzimidazoler
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
NO20021730D0 (no) Ny formulering av mirtazapin
FI990937A0 (fi) Tilaajahallinta
NO20003799L (no) Innkorporering av kolesterol senkende midler i konfekt- dosisformer
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
NO20013795D0 (no) Regulering av anestesi
DE60037197D1 (de) Verwendung funktioneller oraler präparate
NO20016030L (no) Derivater av 4'-demykarosyl-8a-aza-8a-homotylosin
NO20022446D0 (no) Etere av O-desmetyl-venlafaxine
NO20005856L (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
ID23032A (id) Komposisi insektisida
SE9902239D0 (sv) Kornisch bestående av flera delar

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application